Vrooman will share the abstract at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Displaying 41-50 of 63 results matching:
Researchers call for expanding children’s access to experimental cancer therapies
Stand Up To Cancer (SU2C) announced on May 2 that a team led by Kimberly Stegmaier, MD, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Sarah Tasian, MD, Children's Hospital of Philadelphia, was awarded a two-year grant totaling $250,000. Their SU2C Sharp Award is titled: Precision combinatorial immunotherapeutic targeting of thymic stromal lymphopoietin receptor (TSLPR) signaling in pediatric and young adult CRLF2-rearranged ALL.
Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the University of Massachusetts Medical School have developed a strategy to treat two of the most common inherited blood diseases, sickle cell disease and beta thalassemia, applying CRISPR-Cas9 gene editing to patients' own blood stem cells.
The Go4theGoal Foundation (G4TG) recently awarded Brian Crompton, MD, of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, a $50,000 research grant.
The International Society for Stem Cell Research (ISSCR) announced that Scott Armstrong, MD, PhD, is the recipient of its 2019 Tobias Award Lecture.
Pre-treatment with an antibody-drug combination avoids side effects in mice; could substitute for current toxic regimens using chemotherapy or radiation
Multi-center study led by Dana-Farber/Boston Children's contributes to FDA approval of a new treatment for acute lymphoblastic leukemia
The research will focus on adapting gene therapy for use in low-resource areas with high rates of the disease.
In this Vector report, research finds that drugs targeting the TP53 pathway can curb tumor cell proliferation in Ewing sarcoma.